WO2004058146A3 - Novel compositions and methods in cancer - Google Patents

Novel compositions and methods in cancer Download PDF

Info

Publication number
WO2004058146A3
WO2004058146A3 PCT/US2003/040081 US0340081W WO2004058146A3 WO 2004058146 A3 WO2004058146 A3 WO 2004058146A3 US 0340081 W US0340081 W US 0340081W WO 2004058146 A3 WO2004058146 A3 WO 2004058146A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
methods
provides
present
novel compositions
Prior art date
Application number
PCT/US2003/040081
Other languages
French (fr)
Other versions
WO2004058146A2 (en
Inventor
David W Morris
Marc S Malandro
Original Assignee
Sagres Discovery Inc
David W Morris
Marc S Malandro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sagres Discovery Inc, David W Morris, Marc S Malandro filed Critical Sagres Discovery Inc
Priority to AU2003299645A priority Critical patent/AU2003299645B2/en
Priority to CA002508944A priority patent/CA2508944A1/en
Priority to EP03799929A priority patent/EP1581542A4/en
Priority to US10/539,228 priority patent/US20060154250A1/en
Publication of WO2004058146A2 publication Critical patent/WO2004058146A2/en
Publication of WO2004058146A3 publication Critical patent/WO2004058146A3/en
Priority to AU2009200709A priority patent/AU2009200709A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Abstract

The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer and provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.
PCT/US2003/040081 2002-12-17 2003-12-15 Novel compositions and methods in cancer WO2004058146A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003299645A AU2003299645B2 (en) 2002-12-17 2003-12-15 Novel compositions and methods in cancer
CA002508944A CA2508944A1 (en) 2002-12-17 2003-12-15 Novel compositions and methods in cancer
EP03799929A EP1581542A4 (en) 2002-12-17 2003-12-15 Novel compositions and methods in cancer
US10/539,228 US20060154250A1 (en) 2002-12-17 2003-12-15 Novel compositions and methods in cancer
AU2009200709A AU2009200709A1 (en) 2002-12-17 2009-02-19 Novel compositions and methods in cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/322,281 US20040126762A1 (en) 2002-12-17 2002-12-17 Novel compositions and methods in cancer
US10/322,281 2002-12-17

Publications (2)

Publication Number Publication Date
WO2004058146A2 WO2004058146A2 (en) 2004-07-15
WO2004058146A3 true WO2004058146A3 (en) 2004-09-30

Family

ID=32654241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/040081 WO2004058146A2 (en) 2002-12-17 2003-12-15 Novel compositions and methods in cancer

Country Status (5)

Country Link
US (2) US20040126762A1 (en)
EP (1) EP1581542A4 (en)
AU (2) AU2003299645B2 (en)
CA (1) CA2508944A1 (en)
WO (1) WO2004058146A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2465396A1 (en) * 2004-04-20 2005-10-20 Shawn Burgess Rapid integration site mapping
US20060024677A1 (en) * 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
JP2006180738A (en) * 2004-12-27 2006-07-13 Tokyo Univ Of Pharmacy & Life Science New plc-like protein and utilization of the same
WO2006089950A2 (en) 2005-02-26 2006-08-31 Basf Plant Science Gmbh Expression cassettes for seed-preferential expression in plants
US7608413B1 (en) * 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
JP4730733B2 (en) * 2005-05-02 2011-07-20 国立大学法人京都大学 Method for detecting regulatory T cells using expression of type 4 folate receptor as an index, and immunostimulant
JP2007116905A (en) * 2005-10-24 2007-05-17 Natl Inst Of Radiological Sciences Polynucleotide for predicting onset of adverse effect in radiotherapy and method for predicting onset of adverse effect in radiotherapy
EP1920366A1 (en) 2006-01-20 2008-05-14 Glenbrook Associates, Inc. System and method for context-rich database optimized for processing of concepts
AU2007271232A1 (en) * 2006-07-03 2008-01-10 Exonhit Therapeutics Sa Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
EP2134356A2 (en) * 2007-03-05 2009-12-23 Board of Regents, The University of Texas System Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy
US8332209B2 (en) * 2007-04-24 2012-12-11 Zinovy D. Grinblat Method and system for text compression and decompression
WO2009055559A1 (en) * 2007-10-23 2009-04-30 University Of South Florida Method of predicting chemotherapeutic responsiveness of cancer
WO2010111466A1 (en) * 2009-03-27 2010-09-30 The Trustees Of Columbia University In The City Of New York Aptamer-mediated drug release
JP2011244760A (en) * 2010-05-28 2011-12-08 Sumitomo Chemical Co Ltd Treated cell for producing medicament for accelerating regeneration of biotissue
CA2810016A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
US9107892B2 (en) 2010-10-28 2015-08-18 University of Pittsburgh—of the Commonwealth System of Higher Education Identification of a novel retrovirus in patients with benign prostatic hyperplasia
GB201400562D0 (en) 2014-01-14 2014-03-05 Orla Protein Technologies Ltd Protein coated polymeric substrate
US10876109B2 (en) 2015-04-24 2020-12-29 University Of Florida Research Foundation, Inc. Methods of identifying biologically active random peptides in prokaryotic cells and libraries of prokaryotic cells expressing candidate biologically active random peptides
AU2017250756B2 (en) 2016-04-15 2021-04-08 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of B-sarcoglycan and microRNA-29 and the treatment of muscular dystrophy
US11080276B2 (en) * 2018-02-23 2021-08-03 Sap Se Optimal ranges for relational query execution plans
CN109685773B (en) * 2018-12-10 2022-12-06 威海见生生物技术有限公司 Method for determining synapse position points in immune cell image
CN110135312B (en) * 2019-05-06 2022-05-03 电子科技大学 Rapid small target detection method based on hierarchical LCM
EP3980553A4 (en) 2019-06-05 2024-02-28 Liv Process Inc Aptamers against clostridium difficile
US11898146B2 (en) 2020-12-03 2024-02-13 Liv Process, Inc. Aptamers against Clostridium difficile, compositions comprising aptamers against Clostridium difficile and methods of using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057146A2 (en) * 2001-12-26 2003-07-17 Sagres Discovery, Inc. Novel compositions and methods for cancer

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) * 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US5430136A (en) * 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US4892890A (en) * 1984-11-01 1990-01-09 G. D. Searle And Company External analgesic compositions
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5235033A (en) * 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4777127A (en) * 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4938948A (en) * 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4956453A (en) * 1985-12-06 1990-09-11 Cetus Corporation Anti-human ovarian cancer immunotoxins and methods of use thereof
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5359100A (en) * 1987-10-15 1994-10-25 Chiron Corporation Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
US5124246A (en) * 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5206152A (en) * 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5216141A (en) * 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6040138A (en) * 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
ATE139258T1 (en) * 1990-01-12 1996-06-15 Cell Genesys Inc GENERATION OF XENOGENE ANTIBODIES
US5470967A (en) * 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5149655A (en) * 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
US5386023A (en) * 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5602240A (en) * 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (en) * 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5714331A (en) * 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5419966A (en) * 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5644048A (en) * 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
US6107475A (en) * 1992-11-17 2000-08-22 Icos Corporation Seven transmembrane receptors
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5681697A (en) * 1993-12-08 1997-10-28 Chiron Corporation Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor
US5637684A (en) * 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US5580731A (en) * 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5597909A (en) * 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5681702A (en) * 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5759776A (en) * 1995-06-05 1998-06-02 California Pacific Medical Center Targets for breast cancer diagnosis and treatment
US5776683A (en) * 1996-07-11 1998-07-07 California Pacific Medical Center Methods for identifying genes amplified in cancer cells
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6074825A (en) * 1997-07-31 2000-06-13 Maine Medical Center Stable encapsulated reference nucleic acid and method of making
US6153441A (en) * 1998-02-17 2000-11-28 Smithkline Beecham Corporation Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof
AU4187499A (en) * 1998-05-14 1999-11-29 Chiron Corporation Human genes and gene expression products v
AU2001265296A1 (en) * 2000-05-26 2001-12-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
EP1368472A2 (en) * 2001-02-09 2003-12-10 Incyte Genomics, Inc. Molecules for disease detection and treatment
EP1392861A1 (en) * 2001-02-27 2004-03-03 EOS Biotechnology, Inc. Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
AU2002304814A1 (en) * 2001-03-14 2002-11-05 Hybrigenics Protein-protein interactions in adipocytes
US20030104426A1 (en) * 2001-06-18 2003-06-05 Linsley Peter S. Signature genes in chronic myelogenous leukemia
EP1578940A4 (en) * 2002-11-13 2007-12-12 Genentech Inc Methods and compositions for diagnosing dysplasia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057146A2 (en) * 2001-12-26 2003-07-17 Sagres Discovery, Inc. Novel compositions and methods for cancer

Also Published As

Publication number Publication date
AU2009200709A1 (en) 2009-03-12
CA2508944A1 (en) 2004-07-15
US20040126762A1 (en) 2004-07-01
AU2003299645B2 (en) 2008-11-27
AU2003299645A1 (en) 2004-07-22
US20060154250A1 (en) 2006-07-13
EP1581542A4 (en) 2008-06-11
EP1581542A2 (en) 2005-10-05
WO2004058146A2 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
WO2004074320A8 (en) Therapeutic targets in cancer
WO2005031001A3 (en) Novel therapeutic targets in cancer
WO2004058146A3 (en) Novel compositions and methods in cancer
WO2004060304A3 (en) Novel compositions and methods in cancer
WO2005104810A3 (en) Novel therapeutic targets in cancer
WO2005107396A3 (en) Novel compositions and methods in cancer
WO2003008583A3 (en) Novel compositions and methods for cancer
UA90082C2 (en) Isolated monoclonal antibody which binds to and inhibits human cd25
WO2003080808A3 (en) Novel compositions and methods in cancer
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
EP2014669A3 (en) Compositions and methods for cancer
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
MXPA04006517A (en) Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours.
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
AU2003300368A8 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2006038955A3 (en) Novel therapeutic targets in cancer
WO2003045230A3 (en) Novel compositions and methods for cancer
WO2003057146A3 (en) Novel compositions and methods for cancer
WO2004060301A3 (en) Novel compositions and methods in cancer
WO2003053224A3 (en) Novel compositions and methods for cancer
WO2004003155A3 (en) Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
SG148190A1 (en) Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer
WO2004101762A3 (en) Detection and treatment of cancers of the colon
WO2009052255A3 (en) Novel therapeutic targets in bowel disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2508944

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003299645

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003799929

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003799929

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006154250

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10539228

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10539228

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP